Enhanced molecular surveillance in response to the detection of extensively resistant gonorrhoea in Australia

Ella Trembizki; Amy V. Jennison; Cameron Buckley; Amy Bright; Judith Holds; Alison Ward; John Pitt; Stella Pendle; Rob Baird; Kevin Freeman; Jenny Robson; Lebogang Mhango; Kym Lowry; Monica Lahra; David Whiley

doi:10.1093/JAC/DKAA402

Enhanced molecular surveillance in response to the detection of extensively resistant gonorrhoea in Australia

Ella Trembizki, Amy V. Jennison, Cameron Buckley, Amy Bright, Judith Holds, Alison Ward, John Pitt, Stella Pendle, Rob Baird, Kevin Freeman, Jenny Robson, Lebogang Mhango, Kym Lowry, Monica Lahra, David Whiley

Research output: Contribution to journal › Letter › peer-review

2 Citations (Scopus)

Abstract

Ceftriaxone remains the mainstay of treatment for Neisseria gonorrhoeae infection, with no first-line alternatives at this stage. In Australia, since 2017, there have been four documented ceftriaxone-resistant N. gonorrhoeae infections. These involved two infections with the FC428 strain in 2017 (which has since been demonstrated to have spread globally from an unknown geographical source),^1,2 followed by two infections with the A2543 strain in 2018, which also exhibited high-level resistance to azithromycin (.256 mg/L).^3–5 Both FC428 and A2543 strains harbour the penA60.001 allele encoding key PBP2 alterations, A311V and T483S, associated with ceftriaxone resistance.⁵ Three of the four infections reported in Australia were travel associated; all were detected by bacterial culture and considered sporadic.

Original language	English
Pages (from-to)	270-271
Number of pages	2
Journal	Journal of Antimicrobial Chemotherapy
Volume	76
Issue number	1
DOIs	https://doi.org/10.1093/JAC/DKAA402
Publication status	Published - 2021
Externally published	Yes

Keywords

Molecular Surveillance
Detection
Resistant Gonorrhoea

Access to Document

10.1093/JAC/DKAA402Licence: In Copyright

Cite this

Trembizki, E., Jennison, A. V., Buckley, C., Bright, A., Holds, J., Ward, A., Pitt, J., Pendle, S., Baird, R., Freeman, K., Robson, J., Mhango, L., Lowry, K., Lahra, M., & Whiley, D. (2021). Enhanced molecular surveillance in response to the detection of extensively resistant gonorrhoea in Australia. Journal of Antimicrobial Chemotherapy, 76(1), 270-271. https://doi.org/10.1093/JAC/DKAA402

@article{a4de91d8d0e340bca100b3d21fe40b76,

title = "Enhanced molecular surveillance in response to the detection of extensively resistant gonorrhoea in Australia",

abstract = "Ceftriaxone remains the mainstay of treatment for Neisseria gonorrhoeae infection, with no first-line alternatives at this stage. In Australia, since 2017, there have been four documented ceftriaxone-resistant N. gonorrhoeae infections. These involved two infections with the FC428 strain in 2017 (which has since been demonstrated to have spread globally from an unknown geographical source),1,2 followed by two infections with the A2543 strain in 2018, which also exhibited high-level resistance to azithromycin (.256 mg/L).3–5 Both FC428 and A2543 strains harbour the penA60.001 allele encoding key PBP2 alterations, A311V and T483S, associated with ceftriaxone resistance.5 Three of the four infections reported in Australia were travel associated; all were detected by bacterial culture and considered sporadic.",

keywords = "Molecular Surveillance, Detection, Resistant Gonorrhoea",

author = "Ella Trembizki and Jennison, {Amy V.} and Cameron Buckley and Amy Bright and Judith Holds and Alison Ward and John Pitt and Stella Pendle and Rob Baird and Kevin Freeman and Jenny Robson and Lebogang Mhango and Kym Lowry and Monica Lahra and David Whiley",

year = "2021",

doi = "10.1093/JAC/DKAA402",

language = "English",

volume = "76",

pages = "270--271",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "1",

}

Trembizki, E, Jennison, AV, Buckley, C, Bright, A, Holds, J, Ward, A, Pitt, J, Pendle, S, Baird, R, Freeman, K, Robson, J, Mhango, L, Lowry, K, Lahra, M & Whiley, D 2021, 'Enhanced molecular surveillance in response to the detection of extensively resistant gonorrhoea in Australia', Journal of Antimicrobial Chemotherapy, vol. 76, no. 1, pp. 270-271. https://doi.org/10.1093/JAC/DKAA402

TY - JOUR

T1 - Enhanced molecular surveillance in response to the detection of extensively resistant gonorrhoea in Australia

AU - Trembizki, Ella

AU - Jennison, Amy V.

AU - Buckley, Cameron

AU - Bright, Amy

AU - Holds, Judith

AU - Ward, Alison

AU - Pitt, John

AU - Pendle, Stella

AU - Baird, Rob

AU - Freeman, Kevin

AU - Robson, Jenny

AU - Mhango, Lebogang

AU - Lowry, Kym

AU - Lahra, Monica

AU - Whiley, David

PY - 2021

Y1 - 2021

N2 - Ceftriaxone remains the mainstay of treatment for Neisseria gonorrhoeae infection, with no first-line alternatives at this stage. In Australia, since 2017, there have been four documented ceftriaxone-resistant N. gonorrhoeae infections. These involved two infections with the FC428 strain in 2017 (which has since been demonstrated to have spread globally from an unknown geographical source),1,2 followed by two infections with the A2543 strain in 2018, which also exhibited high-level resistance to azithromycin (.256 mg/L).3–5 Both FC428 and A2543 strains harbour the penA60.001 allele encoding key PBP2 alterations, A311V and T483S, associated with ceftriaxone resistance.5 Three of the four infections reported in Australia were travel associated; all were detected by bacterial culture and considered sporadic.

AB - Ceftriaxone remains the mainstay of treatment for Neisseria gonorrhoeae infection, with no first-line alternatives at this stage. In Australia, since 2017, there have been four documented ceftriaxone-resistant N. gonorrhoeae infections. These involved two infections with the FC428 strain in 2017 (which has since been demonstrated to have spread globally from an unknown geographical source),1,2 followed by two infections with the A2543 strain in 2018, which also exhibited high-level resistance to azithromycin (.256 mg/L).3–5 Both FC428 and A2543 strains harbour the penA60.001 allele encoding key PBP2 alterations, A311V and T483S, associated with ceftriaxone resistance.5 Three of the four infections reported in Australia were travel associated; all were detected by bacterial culture and considered sporadic.

KW - Molecular Surveillance

KW - Detection

KW - Resistant Gonorrhoea

UR - http://www.scopus.com/inward/record.url?scp=85098455616&partnerID=8YFLogxK

U2 - 10.1093/JAC/DKAA402

DO - 10.1093/JAC/DKAA402

M3 - Letter

C2 - 33020835

AN - SCOPUS:85098455616

SN - 0305-7453

VL - 76

SP - 270

EP - 271

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 1

ER -

Enhanced molecular surveillance in response to the detection of extensively resistant gonorrhoea in Australia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this